Close this search box.

Annual Report 2023 released


Scantox Group has released the 2023 Annual Report today. It highlights the many activities our company has done over the year to shape the future of a business that in so many ways contribute to improve lives worldwide through the development of new drugs and treatments.

Martin Amtoft-Christensen, CFO Scantox Group : ”We are pleased to deliver a satisfactory operational result in a year with strong organic revenue growth while successfully incorporating two new businesses and look forward to integrating QPS Neuropharmacology in 2024”.

Read the full report